Is Brainstorm Cell Therapeutics Inc. (BCLI) a Buy, Sell, or Hold?
Brainstorm Cell Therapeutics Inc.
OTC:BCLI
$0.97273 USD
$0.01 (1.33%)
- Volume
- 6.96K
- Average Volume
- 17.64K
- Market Capitalization
- $10.73M
- P/E Ratio
- -1.03
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $1.69
- Year Low
- $0.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.02
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Chaim Lebovits |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BCLI |
| CUSIP | 10501E300 |
| CIK | 0001137883 |
| Web | https://www.brainstorm-cell.com |
| Phone | 201 488 0460 |
| Currency | USD |
| Employees | 20 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.14 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Cash Ratio | 0.00 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.60 |
| Price / Cash Flow | -1.61 |
| Price / Book | -0.98 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.11 |
| Trailing P/E Ratio | -1.03 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-10.31M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 109.21% |
| Return on Assets | -1676.01% |
Financials Score
| AltmanZ Score | -661.48 |
| Piotroski Score | 1.00 |
| Working Capital | -11.58M |
| Total Assets | 571K |
| Ebit | -8.91M |
| Market Cap | 10.04M |
| Total Liabilities | 11.76M |
Poll Results
About Brainstorm Cell Therapeutics Inc. (OTC:BCLI) Stock
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical ... trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
2026-06-02 09:00:00
Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science. As the ALS community marks Lou Gehrig Day and reflects on the courage and resilience of those living with the disease, the publication highlights the growing need for regulatory approaches that keep pace with advances in science and the urgent realities faced by patients and families.
2026-05-28 07:45:00
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately.
2026-05-19 08:00:00
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction Highlights and Premium Pricing: The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69.
2026-05-15 16:05:00
NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update. "The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDURANCE study of NurOwn in ALS," said Chaim Lebovits, President and CEO.
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
2026-04-18 04:10:55
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Profitability This table compares Brainstorm Cell
Frequently Asked Questions
-
What is the current Brainstorm Cell Therapeutics Inc. (BCLI) stock price?
-
Brainstorm Cell Therapeutics Inc.(OTC:BCLI) stock price is $0.97273 in the last trading session. During the trading session, BCLI stock reached the peak price of $1.69 while $0.46 was the lowest point it dropped to. The percentage change in BCLI stock occurred in the recent session was 1.33% while the dollar amount for the price change in BCLI stock was $0.01.
-
BCLI's industry and sector of operation?
-
The OTC listed BCLI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCLI?
-
Ibrahim Dagher | Executive Vice President & Chief Medical Officer
Chaim Lebovits | President & Chief Executive Officer
Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary & Director
Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs
Daniel Offen | Chief Scientific Advisor -
How many employees does BCLI have?
-
Number of BCLI employees currently stands at 20. BCLI operates from 1325 Avenue of Americas, New York City, NY 10019, US.
-
Link for BCLI official website?
-
Official Website of BCLI is: https://www.brainstorm-cell.com
-
How do I contact BCLI?
-
BCLI could be contacted at phone #201 488 0460 and can also be accessed through its website. BCLI operates from 1325 Avenue of Americas, New York City, NY 10019, US.
-
How many shares of BCLI are traded daily?
-
The average number of BCLI shares traded daily for last 3 months was 17.64K.
-
What is the market cap of BCLI currently?
-
The market value of BCLI currently stands at $10.73M with its latest stock price at $0.97273